3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Other solid neoplasm
1
Lymphoid
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Carcinoma, Lobular
1
Interventions
Oxaliplatin
300
Fluorouracil
272
Bevacizumab
237
Gemcitabine
236
Leucovorin
212
Capecitabine
207
pembrolizumab
201
Nivolumab
158
Irinotecan
158
Cisplatin
150
Specimen Handling
144
Magnetic Resonance Spectroscopy
130
130-nm albumin-bound paclitaxel
118
Paclitaxel
109
durvalumab
107
Cetuximab
104
Radiotherapy
99
atezolizumab
94
Drug Therapy
94
Biopsy
93
tislelizumab
81
Albumin-Bound Paclitaxel
81
Taxes
74
Folfox protocol
68
lenvatinib
67
Carboplatin
66
regorafenib
60
Blood Specimen Collection
60
sintilimab
54
Ipilimumab
53
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Drugs, Generic
×
Gastrointestinal
×
1 year
×
Clear all
NCT03620643
2025-10-30
ROLo
Royal Marsden NHS Foundation Trust
Phase 2
Completed
33 enrolled
13 charts